As of Wednesday close, Kura Oncology Inc.’s (NASDAQ:KURA) stock was up $0.06, moving up 0.43 percent to $13.99. The average number of shares traded per day over the past five days has been 924,140 shares. 4 times new highs have been achieved over the past 5 days, with a $1.57 gain in that time frame. In the last twenty days, the average volume was 649,540, while in the previous 50 days, it was 613,362.
Since last month, KURA stock rose 30.38%. Shares of the company fell to $9.49 on 04/28/23, the lowest level in the past month. A 52-week high of $19.93 was reached on 01/13/23 after having rallying from a 52-week low of $9.49. Since the beginning of this year, KURA’s stock price has risen by 12.73% or $1.58, and marked a new high 4 times. However, the stock has declined by -29.80% since its 52-week high.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
KURA stock investors should be aware that Kura Oncology Inc. (KURA) stock had its last reported insider trading activity 118 days ago on Jan 27. DALE STEPHEN, the Chief Medical Officer of the company, disposed of 9,225 shares for $13.88 on Jan 27. It resulted in a $128,033 divestment by the insider. FLOWERS KIRSTEN sold 1,906 shares at an average price of $13.89 on Jan 27. The insider now owns 20,605 shares following the transaction. On Jan 27, Chief Operating Officer FORD KATHLEEN sold 1,821 shares at $13.89 apiece. The transaction was valued at $25,294.
In the three months ended March 30, Kura Oncology Inc.’s quick ratio stood at 21.70, while its current ratio was 21.70, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending March 30 was 0.02, and the total debt-to-equity ratio was 0.02. Based on annual data, KURA earned $0.23 million in gross profit and brought in $139.87 million in revenue.
In Kura Oncology Inc.’s quarter-end financial report for March 30, it reported total debt of $9.2 million against cash and short-term investments of $378.84 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. While analysts expected Kura Oncology Inc. to report -$0.54 quarterly earnings, the actual figure was -$0.5 per share, beating the consensus estimate by 7.40%. During the quarter, the company generated -$38.05 million in EBITDA. The liabilities of Kura Oncology Inc. were 30.79 million at the end of its most recent quarter ended March 30, and its total debt was $13.54 million. The value of shareholders’ equity is $68.44 million.
This quick technical analysis looks at Kura Oncology Inc.’s (KURA) price momentum. With a historical volatility rate of 35.75%, the RSI 9-day stood at 80.03% on 24 May.
With respect to its five-day moving average, the current Kura Oncology Inc. price is up by +12.64% percent or $1.57. At present, KURA shares trade +38.10% above its 20-day simple moving average and +14.20% percent above its 100-day simple moving average. However, the stock is currently trading approximately +19.37% above its SMA50 and -9.97% below its SMA200.
Stochastic coefficient K was 91.39% and Stochastic coefficient D was 89.75%, while ATR was 0.76. Given the Stochastic reading of 90.08% for the 14-day period, the RSI (14) reading has been calculated as 72.34%. As of today, the MACD Oscillator reading stands at 0.85, while the 14-day reading stands at 1.33.
Kura Oncology Inc. (KURA) has been rated Buy by analysts. According to 0 brokerage firms, KURA is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate Kura Oncology Inc. stock as buy, with 11 recommending it as overweight.
With a median target price of $31.00, the current consensus forecast for the stock is $22.00 – $47.00. Based on these forecasts, analysts predict Kura Oncology Inc. (KURA) will achieve an average price target of $31.64.